{
    "symbol": "ACAD",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-04 22:35:22",
    "content": " First to drive growth of the NUPLAZID franchise where we continue to outperform market comparators; second, advance our three late-stage opportunities in Alzheimer's disease psychosis, Rett syndrome and the negative symptoms of schizophrenia and third to develop the next wave of CNS breakthroughs with our early stage pipeline together with continuing to pursue strategic business development opportunities. Your line is open. Your line is open. Serge, you want to take that? Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Serge, you want to take that? Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. What I will say without going with all of the details that the day that we had accumulated from the previous Advisory Committee and the previous application and approval with ADP is considerably larger, not only in respect to the controlled trial data, which we added hundreds and thousands of additional patients within this category or frail, the elderly patients, but also with the six years of post-marketing surveillance with about 40,000 and every indication in the day that we see is that we are gradually moving toward a much better balance and toward the balance in regards to the mortality data compared to previous data reported at a previous submission. So from that perspective, we definitely see a favorable trend and as well as what we are seeing in some real-life studies based on the Medicare data and recently reported, we had actually two reports where we are also seeing more favorable profile in terms of mortality when compare pimavanserin to other atypical antipsychotics that are used off-label in the Parkinson's disease psychosis. Your line is open. Your line is open. Serge, you want to take that?"
}